摘要
目的:探讨乙型肝炎病毒(HBV)相关慢加急性肝衰竭(ACLF)患者采用双重血浆分子吸附系统(DPMAS)序贯血浆置换(PE)的治疗效果.方法:选取 2021年 11月—2024年 5月盘州市人民医院收治的 80例HBV相关ACLF患者为研究对象,按随机数字表法将其分为对照组与研究组,各 40例.对照组采用PE治疗,研究组采用DPMAS序贯PE治疗.两组均持续治疗 12周.对比两组肝功能指标、炎症指标、好转情况及并发症发生情况.结果:治疗后,研究组天冬氨酸氨基转移酶、丙氨酸氨基转移酶、白蛋白、直接胆红素、总胆红素水平分别为(51.42±10.12)μmol/L、(55.59±10.14)μmol/L、(24.16±2.05)g/L、(88.86±21.24)μmol/L、(62.63±10.74)μmol/L,均 低 于 对 照 组 的(100.02±26.25)μmol/L、(120.26±12.24)μmol/L、(27.11±2.15)g/L、(162.65±36.37)μmol/L、(121.24±12.33)μmol/L,差异均有统计学意义(P<0.05).治疗后,研究组C-反应蛋白、降钙素原及白细胞介素-6水 平 分 别 为(13.14±2.63)mg/L、(0.56±0.12)ng/L、(14.02±2.06)ng/L,均 低 于 对 照 组 的(19.41±3.05)mg/L、(0.77±0.15)ng/L、(19.94±3.15)ng/L,差异均有统计学意义(P<0.05).研究组好转率为75.00%,高于对照组的 50.00%,并发症发生率为 10.00%,低于对照组的 27.50%,差异均有统计学意义(P<0.05).结论:HBV相关ACLF患者采用DPMAS序贯PE治疗,可促进患者肝功能恢复,减轻炎症反应,降低并发症发生率并提升疾病好转率.
Abstract
Objective:To investigate the efficacy of sequential plasma exchange(PE)with double plasma molecular adsorption system(DPMAS)in patients with acute-on-chronic liver failure(ACLF)associated with hepatitis B virus(HBV).Methods:A total of 80 HBV-related ACLF patients admitted to Panzhou People's Hospital from November 2021 to May 2024 were selected as the study objects,and were divided into a control group and a study group according to random number table method,with 40 cases in each group.The control group was treated with PE,and the study group was treated with DPMAS sequential PE.Both groups were treated for 12 weeks.The indexes of liver function,inflammation,improvement and complications were compared between the two groups.Results:After treatment,The levels of aspartate aminotransferase,alanine aminotransferase,albumin,direct bilirubin and total bilirubin in the study group were(51.42±10.12)μmol/L,(55.59±10.14)μmol/L,(24.16±2.05)g/L,(88.86±21.24)μmol/L,(62.63±10.74)μmol/L,respectively.They were lower than the control group(100.02±26.25)μmol/L,(120.26±12.24)μmol/L,(27.11±2.15)g/L,(162.65±36.37)μmol/L,(121.24±12.33)μmol/L,the differences were statistically significant(P＜0.05).After treatment,the levels of C-reactive protein,procalcitonin and interleukin-6 in the study group were(13.14±2.63)mg/L,(0.56±0.12)ng/L and(14.02±2.06)ng/L,respectively.It was lower than that of control group(19.41±3.05)mg/L,(0.77±0.15)ng/L and(19.94±3.15)ng/L,the differences were statistically significant(P＜0.05).The improvement rate of the study group was 75.00%,which was higher than 50.00%of the control group,and the complication rate was 10.00%,which was lower than 27.50%of the control group,with statistical significance(P＜0.05).Conclusion:DPMAS sequential PE therapy in HBV-associated ACLF patients can promote the recovery of liver function,reduce inflammation,reduce the incidence of complications and increase the rate of disease recovery.
维普
万方数据